Intravenous Injection of Oncolytic Virus Injection (RT-01) in Patients With Relapsed or Refractory T-cell Lymphoma

T-cell Lymphoma Clinical Trial

Official title:

A Sing-Arm, Open Clinical Pharmacology Study of Intravenous Injection of Oncolytic Virus Injection (RT-01) in Patients With Relapsed or Refractory T-cell Lymphoma

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05387226
• Other study ID #: LWY21076CBY3
• Status: Not yet recruiting
• Phase: Phase 1
• Start date: May 2022
• Est. completion date: December 2023

Study information

• Verified date: May 2022
• Source: First Affiliated Hospital Bengbu Medical College
• Contact: zhou huan, MD
• Phone: 13665527160
• Email: zhouhuanbest[@]163.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a single-arm, open-label, clinical pharmacology study to evaluate safety and efficacy of oncolytic virus injection(RT-01) in patients with Relapsed or Refractory T-cell Lymphoma. The purpose of this study is to evaluate the safety and tolerability, antitumor activity, The immunoreactivity, The immunogenicity, pharmacokinetics and virus shedding of RT-01.

Description:

This is an investigator initiated , single-arm, open-label clinical pharmacology study of RT-01 given via Intravenous injection in patients with advanced solid tumors. RT-01 will be administered on days 1 and 6, and every 8 weeks thereafter (up to 6 times).

This study is planned to enroll 6 patients with Relapsed or Refractory T-cell Lymphoma.

The purpose of this study is to assess the safety and tolerability, antitumor activity, The immunoreactivity, The immunogenicity, pharmacokinetics and virus shedding of RT-01.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 6
• Est. completion date: December 2023
• Est. primary completion date: December 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Male or female aged = 18 years.

2. The following of typesRelapsed T-cell lymphoma (TCL): peripheral T-cell lymphoma (PTCL) [peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS), angioimmunoblastic T-cell lymphoma (AITL), anaplastic large cell (ALCL)], and cutaneous TCL (CTCL) of mycosis fungoides (MF).

3. Patients have received at least 1-line systemic treatment in the past and who have relapsed or are refractory: failed to achieve complete remission (CR) or disease progression (PD) after CR, ineligible for autologous hematopoietic stem cell transplantation (ASCT) or PD after ASCT.

4. There is at least one measurable lesion without previous local treatment, which the long axis of the intranodal lesion is >15 mm or extranodal lesion >10 mm According to Lugano 2014 criteria.

5. Patients Eastern Cooperative Oncology Group (ECOG) physical status score must be 0 or 1.

6. Life expectancy=3 months et al.

Exclusion Criteria:

1. Subjects with brain metastasis and/or clinically history tumor brain of metastasis;

2. Subjects who have received anti-tumor therapy such as chemotherapy, radiotherapy, biological therapy, endocrine therapy, targeted therapy, immunotherapy, etc within 2 weeks before RT-01 administration;

3. Subjects who have participate in another interventional study within 4 weeks before RT-01 administration;

4. Subjects who have had major surgery within 4 weeks before RT-01 administration.

5. Patients in any condition requiring systemic treatment with corticosteroids (prednisone > 10 mg/day or equivalent of the similar drug) or other immunosuppressive agents within 14 days before RT-01 administration, but currently or previously treated with any of the following steroid regimens, were included: Topical, ophthalmic, intra-articular, intranasal, or inhaled corticosteroids with minimal systemic absorption; Prophylactic short-term use of corticosteroids;

6. Subjects who have participate in another oncolytic virus study within 8 weeks before RT-01 administration;

7. Subjects received live vaccines within 7 days before RT-01 administration;

8. Subjects received Antiviral drugs within 2 weeks, long-acting interferon within 4 weeks before RT-01 administration# 9.Subjects with adverse reactions caused by previous anti-tumor treatment not recovered to (CTCAE 5.0) grade 1 (except alopecia);

10.Subjects who have uncontrolled active infection; 11.Subjects with known positive history of human immunodeficiency virus (HIV) test or known acquired immunodeficiency syndrome (AIDS); 12.Subjects who have active hepatitis; 13.Subjects who have serious cardiovascular system disorders history; 14.Clinically uncontrollable third space effusion,are considered unsuitable for this study in the opinion of the investigator; 15.Subjects with active autoimmune diseases or history of autoimmune diseases that may relapse; et al.

Related Conditions & MeSH terms

• Lymphoma
• Lymphoma, T-Cell
• T-cell Lymphoma
• Virus

Intervention

Biological:
• Oncolytic Virus Injection(RT-01)
RT-01 will be administered intravenously on day 1 and 6, and every 8 weeks thereafter (up to 6 times)

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
First Affiliated Hospital Bengbu Medical College

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of adverse events	Graded according to the NCI CTCAE version 5.0.	Up to 6 months
Primary	To evaluate objective Response Rate (ORR) of the antitumor activity	To assessed per Lugano and Lyric	Up to 2 years
Primary	To evaluate the disease control rate (DCR) of the antitumor activity	To assessed per Lugano and Lyric	Up to 2 years
Primary	The changes of the immunoreactivity during treatment	Peripheral blood T lymphocyte subtype	Up to 28 days
Primary	To evaluate the immunogenicity of RT-01	Antiviral antibody	Up to 28 days
Primary	To evaluate the viral shedding of RT-01	Viral RNA	8 weeks after last dose
Primary	The Cmax of Viral RNA	The maximum RNA peak concentration	8 weeks after last dose
Primary	The Tmax of Viral RNA	The time of maximum RNA peak concentration	8 weeks after last dose